Therefore, the proper selection of tumor types as well as driver mutations that oncogenically activate the PI3K/Akt/mTOR pathway is essential in achieving the full potential of PI3K/Akt/mTOR inhibitors. The gene discussed is AKT1; the disease is neoplasm.